Pharming Group N.V. stock rating and score history
All changes in ratings, performance and outlook tracked over time.
Pharming Group N.V. stock price, chart patterns and momentum
Recent price movements, trend behaviour and momentum signals based on real-time market data.
What does Pharming Group N.V. do? Business model and key facts
Get the full picture of Pharming Group N.V.: what it builds, where it operates, and how it makes money.
Sector: Healthcare
Industry: Biotechnology
Employees (FY): 404
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Stocks related to Pharming Group N.V.
Selected based on industry alignment and relative market positioning.
Events and news impacting Pharming Group N.V. stock
Earnings, coporate decisions and industry developments that can affect the share price.
Pharming Group N.V. fundamentals and technical analysis
Financial fundamentals and technicals signals combined to access stability, momentum and market direction.
